Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Global Medical REIT (GMRE-PB) Cash from Financing Activities (2016 - 2025)

Global Medical REIT (GMRE-PB) has disclosed Cash from Financing Activities for 14 consecutive years, with -$26.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 17310.46% year-over-year to -$26.3 million, compared with a TTM value of -$10.3 million through Dec 2025, up 53.13%, and an annual FY2025 reading of -$10.3 million, up 53.13% over the prior year.
  • Cash from Financing Activities was -$26.3 million for Q4 2025 at Global Medical REIT, down from -$16.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $58.3 million in Q2 2022 and bottomed at -$84.0 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $708950.0, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 799.03% in 2021, then crashed 17310.46% in 2025.
  • Year by year, Cash from Financing Activities stood at $11.5 million in 2021, then crashed by 239.07% to -$16.0 million in 2022, then increased by 0.87% to -$15.9 million in 2023, then surged by 100.96% to $153000.0 in 2024, then plummeted by 17310.46% to -$26.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for GMRE-PB at -$26.3 million in Q4 2025, -$16.2 million in Q3 2025, and $18.7 million in Q2 2025.